The devices are relatively easy to use but do require hand/breath coordination to ensure the right amount of medication gets ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper ... with a fast action, in a single inhaler. A Viatris spokesperson said: "Viatris obviously ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

AstraZeneca’s Symbicort inhaler accounts for most of its inhalation portfolio revenue, projected by GlobalData to generate a total $2.5bn in 2024. Meanwhile GSK's lead inhalers include Trelegy ...

including inhalers Symbicort, Breztri Aerosphere and Airsupra. The cap will be applicable for patients who are uninsured or underinsured. The announcement follows a similar move by rival company ...